The efficacy and safety of bamlanivimab treatment against COVID-19: A meta-analysis =================================================================================== * Huai-rong Xiang * Bei He * Yun Li * Xuan Cheng * Qi-zhi Zhang * Wen-xing Peng ## ABSTRACT **Background** Bamlanivimab is routinely used in the treatment of coronavirus disease 2019 (COVID-19) in worldwide. We performed a meta-analysis to investigate the efficacy and safety of bamlanivimab treatment in patients with COVID-19. **Methods** We searched articles from Web of Science, PubMed, Embase, the Cochrane Library and MedRxiv between 30 January 2020 and August 5, 2021. We selected randomized clinical trials (RCTs) and observational studies with a control group to assess the efficiency of bamlanivimab in treating patients with COVID-19. **Results** Our meta-analysis retrieved 3 RCTs and 7 cohort studies including 14461 patients. Bmlanivimab may help outpatients to prevent hospitalization or emergency department visit (RR 0.41 95%CI 0.29 to 0.58), reduce ICU admission (RR 0.47 95%CI 0.23 to 0.92) and mortality (RR 0.32 95%CI 0.13 to 0.77) from the disease. The combination of bamlanivimab and etesevimab may had a greater potential for positive treatment outcome. **Conclusion** Bamlanivimab has demonstrated clinical efficacy on mild or moderate ill patients with COVID-19 to prevent hospitalization, reduce severity and mortality from the disease. Combinations of two or more monoclonal antibody increase the effect. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients’ population that could benefit from bamlanivimab are warranted in the future. **Question** Can bamlanivimab treat COVID-19 patients? What are the factors that have great impact on the treatment outcome? **Findings** In this meta-analysis that retrieved 3 RCTs and 7 cohort studies and included 14461 adults, Bmlanivimab may help outpatients to prevent hospitalization or emergency department visit (RR 0.41 95%CI 0.29 to 0.58), reduce ICU admission (RR 0.47 95%CI 0.23 to 0.92) and mortality (RR 0.32 95%CI 0.13 to 0.77) from the disease. **Meaning** In COVID-19 pandemic, the use of bamlanivimab may be warranted. Combinations of two or more monoclonal antibody increase the effect. Key words * bamlanivimab * COVID-19 * Immunotherapy ## INTRODUCTION The Coronavirus disease 2019 (COVID-19) has become a major public hazard caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By August 2021, more than 203 million people have been reported to be infected with COVID-19, and 4 million people have died of it. Although the advent of vaccines has played a great role in epidemic prevention and control. In developing countries, the availability of vaccines has been slow[1]. Several of these COVID-19 therapeutic candidates are currently being studied in preclinical and clinical research stages around the world. Antibody based on viral spike protein (S protein) appears to be the main target of antibody development candidates[2]. Bamlanivimab, also known as LY-CoV555, is a lgG monoclonal antibody which mediate its effects by means of binding with the receptor-binding domain of SARS-CoV-2 to viral neutralization, complement activation and antibody-dependent cellular cytotoxicity[3, 4]. In November 2020, the Food and Drug Administration (FDA) authorized an emergency use authorization (EUA) for bamlanivimab, for treatment of mild to moderate COVID-19 in non-admitted patients at high risk for severe disease[5]. The benefits or harms of such monoclonal antibodies is limited. Thus, this meta-analysis, aims to summaries efficacy of bamlanivimab use in COVID-19 based on available evidence and find out the potential association between treatment with bamlanivimab and outcomes of COVID-19. ## METHOD This meta-analysis was described by the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA-P) statement[6]. and the guidelines of the Meta-analysis of Observational Studies in Epidemiology[7]. The protocol for this study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO, CRD42021272789). ### Search strategy and study selection Two experience researchers (Bei He and Xuan Cheng) based on The Peer Review of Electronic Search Strategies checklist[8] searched Web of Science, PubMed, Embase, the Cochrane Library, MedRxiv for clinical trials and observational studies. A combination of search terminologies (“Coronavirus Disease 2019” OR “COVID-19” OR “SARS-Cov-2” OR “2019-nCoV Diseases” OR “COVID 19 Virus Infection”) AND (“LY-CoV555” OR “bamlanivimab”). Search was down on August 5, 2021 which was imposed restriction on the date between 1.1 2020 to 8.5 2021. No restriction on the geographical location or language of the studies. To be eligible for inclusion, studies must divide patients into treatment group using bamlanivimab and control group with no bamlanivimab. We also required that the studies reported data on any of the pre-determined outcomes. The studies aimed at preventing the occurrence of COVID-19 were excluded. ### Data extraction Two reviewers (Huai-rong Xiang, Yun Li) independently screened the titles and abstracts of the studies to retrieve articles and extracted data based on the inclusion and exclusion criteria. Any discrepancies will be resolved through discussion (with a third author, if necessary). Each included article was thoroughly reviewed, the following data and information were extracted: * (1) The first author’s name, publication date, country and study type. * (2) Patients’ information * (2) Treatment plan (including dosage, timing of using bamlanivimab). * (3) Outcome indicators. Data was extracted and entered to a pre-defined and piloted Microsoft excel database. ### Quality assessment Two reviewers (Qi-zhi Zhang and Huai-rong Xiang) independently evaluated the quality of these literature. In case of any disagreement, the third reviewer (Yun Li) consulted for reconciling any difference of opinion. The version 2 Cochrane Risk of bias Assessment tool[9] was used to evaluate the methodological quality of the RCTs over five domains of selection, performance, blinding, completeness, and reporting. For each domain, risk of bias judgements is ‘high’, ‘unclear’ or ‘low’. The Newcastle-Ottawa Scale (NOS)[10] was to evaluate the quality of the cohort studies which comprises three parts of patient selection, comparability, and research results. The total score is 9 which was divided into three categories: (a) high risk (1-3); (b) some concerns (4-6); (c) low risk (7-9). ### Outcomes and subgroup analyses Primary outcomes were subsequent hospitalization or emergency department (ED) visit, all-cause mortality. Secondary outcomes were admission to intensive care unit admissions. We conducted a priori determined subgroup analyses to explore the source of heterogeneity among observational studies. We performed stratified analyses by (1) the dose of bamlanivimab (700mg, 2800mg, 7000mg and combination) (2) 14 days or 28 days outcomes. ### Statistical Analysis All statistical analysis was conducted by Stata 16 (StataCorp, College Station, SE) software. Statistical heterogeneity was evaluated by the I-squared (I2) test. A fixed-effect model was selected if I2 < 40%. When I2 value > 40%, heterogeneity was considered significant, and the random-effect model was applied. We used relative risk (RR) for dichotomous data with 95% confidence interval (CI). Publication bias was detected using Egger’s test. ### Certainty of evidence The certainty of evidence was rated using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. ## RESULTS ### Search results and study characteristics As shown in Figure. 1, the total search process yielded 460 records. Following removing duplicates publications 243 studies were remained. After screening of titles and abstracts we excluded 156 studies as these include reviews, commentaries, mechanism researches, and irrelevant to COVID-19. After comprehensively screening 77 full texts and assessment of risk of bias, only 10 eligible studies were included, 3 RCTs[11-13] and 7 observational studies[14-20]. We considered observational studies with an NOS score ≥6 with high quality. (Figure 1) All studies included were conducted in America. Assessment of bias for the 9 observational studies revealed a moderate risk of bias as assessed against various quality parameters. (Supplementary table 1). 3 RCTs were classified as low risk because they have been clinically registered in USA National Institutes of Health Register ([ClinicalTrials.gov](http://ClinicalTrials.gov)) and had registration numbers. (Supplementary table 2). Two RCTs[11, 12] shared one registration numbers ([NCT04427501](http://medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04427501&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F26%2F2021.08.24.21262580.atom)), but the patients were enrolled at totally different time. One RCT[11] has four bamlanivimab arm for the dose. Owing to the different dosage and limited studies, we conducted a subgroup analysis based on the infusion time at 700 mg bamlanivimab. ![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/08/26/2021.08.24.21262580/F1.medium.gif) [Figure 1:](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/F1) Figure 1: Preferred Reporting Items for Systematic Review and Meta- analysis (PRISMA) flow diagram for the systematic review and meta- analysis. ### Outcome of bamlanivimab for COVID-19 #### Hospitalization or ED visit Eleven trials (n = 14152 participants) reported on hospitalization or emergency department visit. The use of bamlanivimab compared to placebo could reduce the risk of hospitalizations or emergency department visit (RR 0.41, 95% CI 0.29 to 0.58; *I*2= 77.3%, P = 0.000) with low certainty of evidence. (Figure 2) Sensitivity analysis after deleting the study successively revealed the same high heterogeneity. ![Figure 2:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/08/26/2021.08.24.21262580/F2.medium.gif) [Figure 2:](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/F2) Figure 2: Forest plot of pooled hospitalization or ED visit rate across all included studies. Weights are from random-effects analysis. Note: CI = Confidence Interval, ED = Emergency Department #### Mortality Nine trials (n = 13298 participants) reported on mortality. The use of bamlanivimab compared to placebo could reduce the risk of mortality (RR 0.32, 95% CI 0.13 to 0.77; *I*2= 47.5%, P = 0.064 low certain of evidence). (Figure 3) We conducted a sensitivity analysis to investigate the source of the heterogeneity. The study conducted by Lundgren et al. included hospitalized patients and the heterogeneity may be caused by different degrees of severity of the disease in the participant. After excluding that study, the heterogeneity decreased significantly (*I*2= 9.4%), and the results showed that the bamlanivimab could significantly decrease the rate of mortality. (RR 0.2 95%CI 0.10 to 0.40) ![Figure 3:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/08/26/2021.08.24.21262580/F3.medium.gif) [Figure 3:](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/F3) Figure 3: Forest plot of pooled mortality rate across all included studies. Weights are from random-effects analysis. Note: CI = Confidence Interval. #### ICU admission Only two trials (n = 5073 participants) reported on mortality. The use of bamlanivimab compared to placebo could reduce the risk of ICU admission (RR 0.47, 95% CI 0.23 to 0.92; *I*2= 0.0%, P = 0.672 low certainty of evidence). (Figure 4) We did not perform sensitivity analysis. ![Figure 4:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/08/26/2021.08.24.21262580/F4.medium.gif) [Figure 4:](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/F4) Figure 4: Forest plot of pooled ICU admission rate across all included studies. Weights are from random-effects analysis. Note: CI = Confidence Interval. #### Safety In this meta-analysis, 3 RCTs[11-13] reported adverse effects. The pooled result from three trials (n = 1873 participants) found bamlanivimab increased the risk of serious adverse events but no statistic difference. (RR 1.33 95% CI 0.84 to 2.10; *I*2 = 0%, P = 0.783 high certainty of evidence) (Figure 5) We did not perform sensitivity analysis about this result. ![Figure 5:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/08/26/2021.08.24.21262580/F5.medium.gif) [Figure 5:](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/F5) Figure 5: Forest plot of pooled serious adverse events rate across all included studies. Weights are from Fixed-effects analysis. Note: CI = Confidence Interval. ### Subgroup Analysis #### Subgroup analysis based on dose Subgroup analysis showed that the 700mg single bamlanivimab and 2800mg bamlanivimab plus 2800mg etesevimab could reduce the risk of hospitalizations or ED visit compared with the control group. And the combination of two antibodies could reduce more risk than 700mg single antibody (RR:0.29 VS 0.59). Due to only one study in the 2800mg single dose and 7000mg dose, there are no statistic difference between treatment and control group. (Figure 6) ![Figure 6:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/08/26/2021.08.24.21262580/F6.medium.gif) [Figure 6:](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/F6) Figure 6: Forest plot for subgroup analysis of hospitalization or ED visit rate by type of dose. Weights are from random-effects analysis. Note: CI = Confidence Interval. 2800mg B and 2800 E = 2800mg bamlanivimab plus 2800mg etesevimab In the part of mortality, there was no significant difference among 7000mg treatment group and control group. Both 700mg and 2800mg bamlanivimab plus 2800mg etesevimab could decrease the mortality (700mg: RR 0.33 95%CI 0.18 to 0.58; *I*2 = 0%, P=0.799. 2800mg bamlanivimab plus 2800mg etesevimab: RR 0.05 95%CI 0.00 to 0.81) (Figure 7) ![Figure 7:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/08/26/2021.08.24.21262580/F7.medium.gif) [Figure 7:](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/F7) Figure 7: Forest plot for subgroup analysis of mortality rate by type of dose. Weights are from random-effects analysis. Note: CI = Confidence Interval. 2800mg B and 2800 E = 2800mg bamlanivimab plus 2800mg etesevimab ### Risk of publication bias Assessment of publication bias using Egger’s test showed that there was significant potential publication bias among the included trials hospitalization or ED visit (p=0.001) and mortality (p=0.006). (Supplementary Figure 1) ## DISCUSSION This is the first meta-analysis included 3 RCTs and 9 observational studies investigating the effect of bamlanivimab with or without etesevimab on clinical outcomes. Despite our inclusion criteria that did not specify the severity of the disease, all the studies were conducted with non-hospitalized patients except the RCT by Lundgren 2020 et al[13]. This study provided better evidence for COVID-19 treatment decisions through systematically reviewed, summarized evidence. And our meta-analyses suggested that bamlanivimab may help outpatients to prevent hospitalization, reduce severity and mortality from the disease. What’s more, the combination of bamlanivimab and etesevimab could play a bigger role in the outcomes. Last but also important, early treatment is more effective. There is slightly trend on increasing serious adverse events. The certainty of the evidence of the all-cause hospitalization or ED visit and mortality was low. All observational studies adjust the age confounders, but patients in exposed group had higher risk factor for severe COVID-19 than nonexposed group. And there still was a trend toward a lower risk of hospitalization in bamlanivimab treated patients. Most studies’ patients we included were at mild or moderate severity COVID-19. Only one RCT[13],included hospitalized patients whose infusion time was within 12 days of symptom onset, which announced that no clinical benefit of bamlanivimab administration in patients with already present symptoms of COVID-19. Another study[21] showed the contrary results which only treated to hospitalization. But early intervention of this study is rather comparable to the recently outpatient studies. It has been proposed that bamlanivimab has ability to neutralize the spike protein of SARS-CoV-2 and consequently block attachment to the human angiotensin-converting enzyme 2 (ACE-2) receptor and deny host cell entry. The FDA announced that bamlanvimab has a definite therapeutic effect on COVID-19. However, Lilly, the company that makes bamlanivimab suggested that it would be unlikely to help patients who admitted to hospital with COVID-19. What’s more, potential drawbacks of monoclonal antibodies have also become clear, such as immune escape by selection of viral mutations[22]. For instance, E484K-carrying SARS-CoV-2 variants could resistant to bamlanivimab which emergence and expansion of had been at least partially underestimated[23] And bamlanivimab lost its ability to bind to the spike protein and no longer neutralized the Delta variant[24, 25]. Combinations of two or more monoclonal antibodies or polyclonal antisera may therefore increase the barrier sufficiently to prevent escape of the immune system as known from other viral infections[26]. There are some limitations on our meta-analysis. First, groups in some studies were unlikely considered to be comparable on each variable used in the adjustment such as immunosuppression and comorbidity. Second, the small number of participants in some RCTs may increase the likelihood of type II statistical error. Larger scale RCTs are required to confirm the findings. Third, the primary focus of this meta-analyses was cohort studies. Theoretically, observational studies would overestimate the treatment effect of the interventions [27]. Fourth, the data were too limited to perform more meaningful outcome or subgroup analyses. Fifth, the results of egger’s test mean there were high risk of selective reporting or of publication bias. ## Conclusion Our study showed that bamlanivimab has might be beneficial for mild or moderate ill patients with COVID-19. Combinations of two or more monoclonal antibody increase the effect. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients’ population that could benefit from bamlanivimab are warranted in the future. ## Data Availability All data relevant to the study are included in the article or uploaded as supplementary information. ## Authors’ Contributions Wen-xing Peng, and Huai-rong Xiang designed this study; Xuan Cheng and Bei He ran the searched strategy; Huai-rong Xiang and Yun Li selected articles and extracted data; Qi-zhi Zhang and Yun Li evaluate the quality of the literature. Huai-rong Xiang wrote the manuscript, Xuan Cheng, Yun Li, Bei He and Qi-zhi Zhang edited. All listed authors reviewed and approved the final manuscript. ## Competing interests The authors declared there are no competing interests. ## Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. The data are available by accessing the published studies listed in table 1. View this table: [Table 1](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/T1) Table 1 Characteristics of the studies included in the meta□analysis View this table: [Table 2.](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/T2) Table 2. Outcome summary ![](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/08/26/2021.08.24.21262580/F8/graphic-15.medium.gif) [](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/F8/graphic-15) ![](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/08/26/2021.08.24.21262580/F8/graphic-16.medium.gif) [](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/F8/graphic-16) Figure 1: Risk of publication bias. (a)hospitalization or ED visit; (b)mortality View this table: [Table 1.](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/T3) Table 1. Risk of bias summary: the r eview authors’ judgments about each risk-of-bias item for each included cohort study. View this table: [Table 2:](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/T4) Table 2: Risk of bias summary: the review authors’ judgments about each risk-of-bias item for each included randomized control trial. View this table: [Table 3:](http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262580/T5) Table 3: GRADE summary of findings on use of intravenous immunoglobulin in COVID-19 ## Acknowledgments None * Received August 24, 2021. * Revision received August 24, 2021. * Accepted August 26, 2021. * © 2021, Posted by Cold Spring Harbor Laboratory The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission. ## Reference 1. [1].Tyagi K, A Ghosh, D Nair, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr. 2021;15(3):1007–1008. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.dsx.2021.05.001&link_type=DOI) 2. [2].Baral PK, J Yin, MNG James. Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. Int J Biol Macromol. 2021;186:490–500. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ijbiomac.2021.07.013&link_type=DOI) 3. [3]. Casadevall AE Dadachova, LA Pirofski. Passive antibody therapy for infectious diseases. #N/A. 2004;2(9):695–703. 4. [4].Dale AP, MJ Hudson, T Cullen, et al. Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona. J Am Med Dir Assoc. 2021;22(7):1357–1358. 5. [5].COVID-19 news release: FDA authorizes monoclonal antibody for treatment of COVID-19. US Food and Drug Administration website. Available from: [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19). 6. [6].Moher D, A Liberati, J Tetzlaff, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pmed.1000097&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19621072&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F26%2F2021.08.24.21262580.atom) 7. [7].Stroup DF, JA Berlin, SC Morton, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.283.15.2008&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=10789670&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F26%2F2021.08.24.21262580.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000086436600037&link_type=ISI) 8. [8].McGowan J, M Sampson, DM Salzwedel, et al. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40–46. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jclinepi.2016.01.021&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27005575&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F26%2F2021.08.24.21262580.atom) 9. [9].Higgins JP, DG Altman, PC Gotzsche, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNDMvb2N0MThfMi9kNTkyOCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzA4LzI2LzIwMjEuMDguMjQuMjEyNjI1ODAuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 10. [10].Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10654-010-9491-z&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20652370&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F26%2F2021.08.24.21262580.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000282102200001&link_type=ISI) 11. [11].Gottlieb RL, A Nirula, P Chen, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: a Randomized Clinical Trial. JAMA. 2021;325(7):632–644. [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F26%2F2021.08.24.21262580.atom) 12. [12].Dougan M, A Nirula, M Azizad, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. New Engl J Med. 2021. 13. [13].Lundgren JD, B Grund, CE Barkauskas, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. New Engl J Med. 2021;384(10):905–914. [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F26%2F2021.08.24.21262580.atom) 14. [14].Rainwater-Lovett K, JT Redd, MA Stewart, et al. Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States. Open Forum Infect Dis. 2021;8(8):ofab398. 15. [15].Ganesh R, CF Pawlowski, J. O’Horo, et al. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. J Clin Invest. 2021. 16. [16].Kumar RN, EL Wu, V Stosor, et al. Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021. 17. [17].Iqbal L, TJ Terlau, A Hernandez, et al. Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community. Cureus. 2021;13(7). 18. [18].Destache CJ, SJ Aurit, D Schmidt, et al. Bamlanivimab Use in Mild-to-Moderate COVID-19 Disease: A Matched Cohort Design. Pharmacotherapy. 2021. 19. [19].Bariola JR, EK McCreary, RJ Wadas, et al. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality among Nonhospitalized Adults with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. #N/A. 2021;8(7). 20. [20].Webb BJ, W Buckel, T Vento, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open Forum Infect Dis. 2021;8(7):ofab331. 21. [21].Koehler J, B Ritzer, S Weidlich, et al. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. Infection. 2021:1–6. 22. [22].Schoofs T, F Klein, M Braunschweig, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016;352(6288):997–1001. [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEyOiIzNTIvNjI4OC85OTciO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8wOC8yNi8yMDIxLjA4LjI0LjIxMjYyNTgwLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 23. [23].Tuccori M, I Convertino, S Ferraro, et al. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021:1–12. 24. [24].Planas D, D Veyer, A Baidaliuk, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–280. 25. [25].Connor BA, M Couto-Rodriguez, JE Barrows, et al. Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case. Int J Infect Dis. 2021. 26. [26].Margolis DM, RA Koup, G Ferrari. HIV antibodies for treatment of HIV infection. Immunol Rev. 2017;275(1):313–323. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/imr.12506&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28133794&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F08%2F26%2F2021.08.24.21262580.atom) 27. [27].Vandenbroucke JP. Why do the results of randomised and observational studies differ? Bmj. 2011;343:d7020. [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNDMvbm92MDdfMS9kNzAyMCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzA4LzI2LzIwMjEuMDguMjQuMjEyNjI1ODAuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)